RFK Jr. Unapproved Peptides Plan Hits Pharmacies

The federal government just made unapproved peptides a lot easier to get, and the wellness corner of your feed is about to get louder. Health Secretary Robert F. Kennedy Jr. released a plan this week that would let compounding pharmacies mix six popular injectables that the FDA has never signed off on, according to the BBC.

What the plan actually does

The draft was posted in the Federal Register on Wednesday. It says the Department of Health and Human Services will use enforcement discretion, which is a formal way of looking the other way, when small compounding pharmacies prepare the peptides, as NPR reported on Morning Edition. These compounds have not gone through the FDA's drug review and approval process.

The BBC says the named list includes BPC-157, TB-500, KPV, MOTS-c and Semax. After the plan is officially published later this week, a two-week public comment period will follow. That is a very short window for a decision this big.

An unusual way to do it

Here is the twist. The draft came from the office of the health secretary rather than from the FDA, which the BBC described as an unusual move. Normally the agency that reviews drugs leads on this kind of call.

It also runs against the FDA's own staff. An FDA advisory panel voted in July to loosen restrictions on the six peptides, but FDA staff members recommended against it, according to the BBC. Kennedy has called himself a "big fan" of the drugs and has promised to ease limits that were tightened under the Biden administration.

Why peptides are all over your For You page

Peptides are short chains of amino acids that the body already makes. They act like messengers, telling cells what to do, and they matter for skin health, immune function and hormone regulation. Insulin is one of the first peptide hormones ever found, and it has helped people with diabetes for more than a century.

The unregulated version is a different scene. Peptides exploded in the wellness market after GLP-1 weight loss drugs went mainstream. Influencers sell them in "stacks" and pitch them as a shortcut to looking younger, healing faster or glowing skin.

The BBC reports they have also caught on with teens on TikTok, especially boys, who chase muscle gains tied to biohacking and looksmaxxing trends. Those claims are unproven. Many of these products used to be sold online with the label "not for human consumption."

What the experts are worried about

Health experts have warned that there are no human clinical trials behind most of these compounds and that long-term effects are unknown. That is the core problem with unapproved peptides: nobody can say what a stack does to a teenager after a year.

Compounding is also a different safety story than a factory-made drug. A pharmacy mixing a custom injectable is not held to the same approval process, so quality can vary from one batch to the next. The BBC said it contacted the FDA for comment.

The same week, a bigger health push

The peptide news landed alongside other moves from the department. Kennedy was in Des Moines, Iowa, on Thursday, where HHS announced a proposed update to infant formula nutrient rules, the first major review in nearly thirty years, along with five hundred million dollars for home-visit programs, according to HHS. Those are separate stories, but together they show how fast this agenda is moving.

What to watch next

The comment period is the next real checkpoint. Doctors, pharmacists and patient groups can weigh in, and the final shape of the policy may shift. Until then, the practical advice from the health experts quoted by the BBC is simple: do not treat an influencer's stack as medicine.

If you are curious about wellness trends, it helps to separate hype from evidence. A viral protocol with great before and after photos is still not a clinical trial. For more on the science behind the headlines, check the health desk and the politics desk on GenZ NewZ.

The bottom line is that unapproved peptides are heading from gray market to pharmacy counter faster than the research is. Whether that is a win for access or a gamble with young people's health is the argument that will play out over the next two weeks.